During physiological development and after a stressor event, vascular cells communicate with each other to evoke new vessel formation-a process known as angiogenesis. This communication occurs via direct contact and via paracrine release of proteins and nucleic acids, both in a free form or encapsulated into micro-vesicles. In diseases with an altered angiogenic response, such as cancer and diabetic vascular complications, it becomes of paramount importance to tune the cell communication process. Endothelial cell growth and migration are essential processes for new vessel formation, and pericytes, together with some classes of circulating monocytes, are important endothelial regulators. The interaction between pericytes and the endothelium is facilitated by their anatomical apposition, which involves endothelial cells and pericytes sharing the same basement membrane. However, the role of pericytes is not fully understood. The characteristics and the function of tissue-specific pericytesis are the focus of this review. Factors involved in the cross-talk between these cell types and the opportunities afforded by micro-RNA and micro-vesicle techniques are discussed. Targeting these mechanisms in pathological conditions, in which the vessel response is altered, is considered in relation to identification of new therapies for restoring the blood flow.
Introduction
Despite the large amount of data describing the important role of pericytes in controlling vascular homeostasis, the nature of these cells is still controversial. Lack of specific markers, the associated difficulty to unequivocally identify them, and vast organ-specific differences in number and morphology observed in the pericytes from different source, make pericytes a neglected cell type. Pericytes have been attracting the attention of scientists and clinicians due to increasing body of evidence showing their regenerative properties. Being of mesenchymal nature, pericytes not only finely tune the angiogenic process, but they also retain their plasticity and ability to differentiate into other cell type in a tissue specific manner.
The first description of pericytes dates back to the late 1800s when Eberth and Rouget described them as adventitial/mural cells juxtaposed to capillary endothelial cells (ECs). In 1923, Zimmerman coined the term pericyte referring to their location adjacent to capillaries and embedded within the same basement membrane (BM) (Diaz-Flores et al., 2009 ). The advent of electron microscopy has helped better define pericytes' anatomical position and morphology. They were described as the cells residing around the endothelial wall of capillaries, having a huge nucleus oriented towards the albuminal side of capillary vessel and with elongated structures that the cell uses to directly interact with underneath endothelium (Allt & Lawrenson, 2001) . Depending on the vascular bed and their differentiation state, pericytes exhibit varying morphologies ranging from typical flat and stellate shape in the central nervous system (CNS), to a more rounded shape in kidneys (Armulik et al., 2011) .
Most pericytes are identified by the expression of CD146, alpha smooth muscle actin (α-SMA), neural/glial antigen 2 (NG2) and platelet-derived growth factor receptor-β (PDGFR-β) markers, although some exceptions exist. For instance, α-SMA is not noticeably expressed in skin and CNS. The pericytes from capillaries are NG2 + /α-SMA − , whereas pericytes from arterioles and venules are respectively NG2 + / α-SMA + and NG2 − /α-SMA +, but all equally express CD146 and the PDGFR-β (Crisan et al., 2012) . The pericyte density differs between organs and depends on the stringency of endothelial barrier function (van Dijk et al., 2015) . The blood brain barrier or the blood retinal barrier shows 1:1 pericytes/ ECs ratio in order to control para-cellular and transendothelial flow, avoiding perturbation of the delicate and highly specialized tissue. Also, higher coverage is observed in the capillaries of lower extremities, which have to counteract orthostatic blood pressure (Sims, 2000) . Conversely, human lung and skin have an estimated 10:1 pericytes/ ECs ratio. In skeletal muscle the pericytes/ECs ratio was estimated 100:1 even though this evidence is not robust.
Pericytes-ECs communication and vessel stabilization are crucial for the physiology of blood vessels and an impaired stabilization leads to aberrant (excessive or poor) vascularisation typical of vessel pathologies, e.g. diabetic complications, tumor growth and metastasis, kidney diseases or neurodegenerative disorders.
In this article we review the current knowledge on pericytes paracrine interaction with the endothelial cells and discuss the potential strategies to improve it.
The multifaceted nature of pericytes: tissue-specific differences
Tissue-specific marker expression of pericytes has been better characterized when researchers attempted to isolate them from different organs. Being that pericytes are crucial modulator of EC function, it was clear that a better understanding of pericytes biology could help develop new therapeutic strategies for pathological conditions in which angiogenesis was impaired. Moreover, pericytes represent a class of cells that could be exploited in regenerative medicine due to their mesenchymal nature that confers their plasticity and ability to differentiate in other cell types. From these isolation/expansion/characterization studies we have learned that pericytes can be subdivided in specialized subclasses that generally resembled the tissue of origin in terms of markers expression and differentiation capacities. For instance, pericytes from the retina were extensively studied, obtained from the retinal surgical leftovers from patients affected by diabetic retinopathy. This is a condition in which the vascular tree is aberrantly increased, and retinal pericytes highly express α-SMA and NG2 (Miller et al., 2006) . In subjects with diabetic retinopathy, NG2 pericytes also highly express connective tissue growth factor (CTGF) compared with non-diabetic subjects. CTGF expression is induced by transforming growth factor-β (TGF-β), vascular endothelial growth factor-A (VEGF-A), advanced glycation end-products (AGEs) and plays a role in extracellular matrix (ECM) production and thickening of capillary basement membrane in the retina (Kuiper et al., 2004) .
In the CNS, pericytes contribute to the formation of the blood brain barrier, whereby they express PDGFR-β, NG2, and nestin, and locate in between endothelial cells and astrocytes. This is a strategic location since they can differentiate into both of these cell lines and astrocytes tightly envelope the pericyte-endothelial unit with long processes that enter the basal membrane (Hawkins & Davis, 2005) . Recently Nakagomi and co-workers demonstrated that brain pericytes can be reprogrammed by hypoxia in vitro and can differentiate both into vasculogenic and neurogenic cells when cultured in proper differentiation media. The different fate is evidenced by the expression of different markers like CDH5, endoglin, thrombomodulin and other markers typical of vascular cells or alternatively Tuj1 or MAP2 when they enter the neuronal path (Nakagomi et al., 2015) .
Dermis pericytes from foreskin were isolated and selected for the expression of 3G5 antigen, a useful marker of pericytes in normal human skin because it is not shared by fibroblasts, the most abundant cell type in the skin. Those pericytes also expressed α-SMA and vimentin while being negative for the expression of endothelial markers (Helmbold et al., 2001) . Others isolated dermis pericytes using a combination of 3G5 antigen, PDGFR-β and/or high molecular weight melanoma associated marker (HMW-MAA-marker of pericyte activation). Those pericytes were shown to express ANGIOPOIETIN (Ang)-1 but not Ang-2 or Tie2 which were expressed by ECs from the same tissue (Sundberg et al., 2002) .
A landmark paper in the field of pericytes control of angiogenesis was published by Campagnolo et al. who demonstrated that the adventitia of saphenous vein holds a population of CD34
− cells expressing also the typical pericyte markers PDGFR-β and NG2. Those pericytelike cells are located in the close vicinity to adventitia of vasa vasorum and once isolated they lost the CD34 positivity but retained pericyte markers that rather increase upon differentiation. Isolated saphenous vein pericytes (SVPs) were able to promote ECs tubulization when co-cultured on matrigel in vitro. Upon contact with ECs, SVPs were also able to reorganize N-cadherin, which was polarized on pseudopodia. Saphenous vein pericytes were also able to shed the pro angiogenic Ang-1 in the culture medium, thus fostering ECs tubulisation in a paracrine way (Campagnolo et al., 2010) . Cossu and Dellavalle demonstrated, for the first time, the existence of pericytes in the vascular compartment of skeletal muscle, which show myogenic differentiation ability and can differentiate spontaneously in myotubes, thus contributing to muscle regeneration. These cells express annexin V, alkaline phosphatase (ALP), desmin, vimentin and PDGFR-β at high levels together with α-SMA and NG2 but they do not express ECs (CD31) or myotube (CD56) and myogenic (MyoD, Myf5 and myogenin) characteristic markers. Indeed, when injected in the muscle of mouse dystrophic models, skeletal muscle pericytes formed efficiently dystrophin expressing myotubes (Dellavalle et al., 2007) . The hypothesis of myogenic potential of muscle pericytes was further consolidated by the observation in mouse models that following a tissue loss, pericytes fuse with the developing myofibres and enter the satellite cell compartment (Dellavalle et al., 2011) . Conversely, Meng recently demonstrated that human CD133 + progenitors but not pericytes
give rise to Pax7 + satellites when transplanted into murine models of dystrophy. The possibility that pericyte can differentiate into satellite cells needs further investigation. We recently showed that muscle pericytes from pigs are angiogenic in vitro and that culturing in a PEGbased hydrogel scaffold significantly improved their myogenic differentiation and angiogenic potentials in vitro and in vivo (Fuoco et al., 2014 ). An additional level of classification of muscle pericytes leads to two classes: Type-1 and Type-2 pericytes based on specific differential marker expression and functions. Type 1 pericytes are characterized for being nestin − /NG2 + and are the only pericyte subpopulation expressing PDGF-α involved in fibrosis and adipogenesis in skeletal muscle (Birbrair et al., 2012b) . Type-2 pericytes are characterized by being nestin + /NG2 + and are highly myogenic, angiogenic and prone to a neurogenic fate under optimized culture conditions. However, the neurogenic differentiation potential needs further confirmation (Birbrair et al., 2015) . Several studies postulated that pericytes isolated from adipose tissue are prone to adipocyte differentiation. These cells express peroxisome proliferator-activated receptor gamma (PPARγ) in addition to the canonical PDGFR-β, NG2, and α-SMA markers. However, pericytes from other sources also accumulate fat droplets in adipogenic culture conditions (Paquet-Fifield et al., 2009; Birbrair et al., 2015) therefore such feature is not exclusive of adipose tissue-derived pericytes.
Although pericytes have been isolated from different tissues these sources are limited to small amount of material. On the contrary, placenta is an abundant source from which pericytes can be isolated. Usually, pericytes are isolated from placental vessel fragments by outgrowth without positive selection. Those cells express NG2, calpoin, Thy-1, PDGFR-β and CD146 while being negative for endothelial (CD31, CD34), leukocyte (CD45, CD14) and differentiated smooth muscle cells (SMCs) markers (SM22α and smooth Muscle Myosin Heavy chain-SMMHC). Moreover, once implanted together with ECs in mouse models they increase ECs angiogenic properties (Maier et al., 2010) .
Pericytes are easy to isolate ideally from every vascularised tissue; however, there is an urgent need for a standardized selection method as well as unique pericyte markers, especially in the perspective of using these cells as an autologous source for regenerative medicine.
Pericytes interact with endothelial cells for tissue homeostasis and regeneration
Pericytes and ECs are embedded within the same BM produced through contribution of both cell types. However, the BM is interrupted at multiple discrete points where pericytes and ECs contact each other in different ways. Diverse contact structures have been described: "peg and socket" interactions are located at the site of pericytes-ECs inter-digitations; occluding plaques, gap junction-like structures and adhesion plaques were also described. At adhesion plaque sites, the intercellular space between the two cell types is enriched in fibronectin, possibly interacting with the extra-junctional N-cadherin on ECs (Larson et al., 1987; Tillet et al., 2005; von Tell et al., 2006) . The type of junctions and their number varies according to the tissutal district (Allt & Lawrenson, 2001 ) being less numerous and more tight in barrier microvasculature like in the CNS. The existence of diverse junctional structures preludes an intense chemical (passage of molecules between cells) and mechanical (transmission of contractile force) communication between the two cell types. However most of pericytes and ECs communication is exerted by the paracrine mechanisms (Fig. 1) . The paracrine crosstalk between pericytes and ECs is a determinant in the regulation of angiogenesis and vessel stabilization and is regulated by diverse molecules and pathways. Detailed description of some of the crucial paracrine regulators follows.
Vascular endothelial growth factor-A and platelet-derived growth factor beta
During angiogenesis the first molecular players responsible respectively for BM degradation and vessel sprouting are the growth factor VEGF-A and proteases of the class of matrix metalloproteinases (MMPs). Following the initial VEGF-A cues produced by cells that need blood supply, pericytes detach from the endothelium while ECs proliferate and migrate forming a new growing vessel, which develops within the surrounding tissue. VEGF-A is not only secreted but also sequestered in the BM and MMPs activity contributes to its liberation (Arroyo & Iruela-Arispe, 2010; Potente et al., 2011) .
The growing new vessel is susceptible to degradation and needs to be covered by pericyte to be stabilized. This is possible thanks to a strict interplay between pericytes and ECs which relay on the passage of functional and regulatory molecule between the two cell types some of which influence the physiology of one type whereas others regulate both (Trost et al., 2016) . ECs from the growing vessels secrete plateletderived growth factor beta (PDGF-B) which interacts with PDGFR-β on pericytes and triggers their recruitment to stabilize the nude capillary tube. The PDGF-B and PDGFR-β signaling network exerts a vital role in the pericyte recruitment to the vessels that are being newly formed (Hoch & Soriano, 2003; . Specifically, PDGF-B ligand is secreted from endothelial cells during sprouting angiogenesis, which binds to PDGFR-β on the pericytes and activates a signaling cascade that drives their proliferation and migration during maturation of the vessels. It has been shown that mice deficient of PDGF-B and PDGFR-β exhibit resembling phenotypes, comprising prenatal death due to an endothelial dysfunction (Leveen et al., 1994; Soriano, 1994) ; these abnormalities arise from loss of pericytes (Lindahl et al., 1997; Crosby et al., 1998 ) that lead to endothelial hyperplasia and abnormal vascular morphogenesis (Hellstrom et al., 2001 ). Interestingly, PDGF-B is not required for initial induction of pericytes, but c-b knockout prevents pericytes from expansions and spreading along the microvessels (Hellstrom et al., 1999) . Moreover, Bjarnegård et al. demonstrated that endothelium-specific genetic deletion of pdgf-b results in depletion of pericytes (Bjarnegard et al., 2004) , thus the endothelial cell is the main source of PDGF-B. It has been also noted that the levels of PDGF-B reflect the amount of the recruited pericytes; in particular, Hammes et al. presented evidence that mice heterozygous for pdgf-b knockout (PDGF-B (+/−) possessed 30% less retinal pericytes than the wild-type (Hammes et al., 2002) . It is important to note that the expression of PDGF-B is significant only at sites of active angiogenesis (Hellstrom et al., 1999) . PDGF-B possesses a C-terminal retention motif, which allows its binding to heparan sulfate proteoglycans (HSPG) in the extracellular matrix or on the cell surface upon secretion from tip cells (Ostman et al., 1991) . This extracellular retention of PDGF-B promotes its limited range of action (Eming et al., 1999) , which allows strong pericyte adhesion to the vessel wall upon interaction of ECM-bound PDGF-B and PDGFR-β on pericytes (Lindblom et al., 2003) . In a recent study, Arimura et al. demonstrated that in rats with middle cerebral artery occlusion (MCAO) PDGF-B secreted from endothelial cells in peri-infarcted areas induces significant Akt phosphorylation in PDGFR-β-expressing brain pericytes; this in turn promotes pericyte growth and anti-apoptotic responses, which may play an important role in neuroprotection following an ischemic stroke (Arimura et al., 2012) . The maintenance of this ligand-receptor interplay is necessary for a proper angiogenesis to occur. In humans, null or loss of function mutations on both PDGF-B and PDGFR-β in heterozygosis leads to the onset of a pathology called primary familial brain calcification (PFBC), characterized by brain vessel calcifications. Calcific lesions occur in the capillary basement membrane possibly accumulate inside the pericytes (Vanlandewijck et al., 2015) . Conversely an increased expression of PDGF-B is associated with an increased angiogenesis in different type of tumors. In hepatocellular carcinoma for instance, the hypoxia induced production of PDGF-B activates stellate cells (specialized liver pericytes) to interact with endothelial cells in promoting tumor angiogenesis (Lu et al., 2015) . It is estimated that around 30% of gliomas are correlated to an up-regulation of PDGF ligands. As an example, PDGF-B up-regulation is involved in the pathogenesis of glioblastoma multiforme an aggressive form of brain tumors. In this context PDGF ligands induce the recruitment of tumor unrelated cells which contribute to the tumor mass growth and also stimulate the formation of aberrant, leaky vessels (Fomchenko et al., 2011; Zheng et al., 2016) .
Sphingosine-1-phosphate
Other factors co-operate with PDGF-B/PDGFR-β signaling in recruitment of pericyte during angiogenesis. Sphingosine-1-phosphate (S1P) is secreted by pericytes and interacts with ECS via a G-protein coupled receptor known as S1P1-5; upon binding to its receptor, S1P facilitates adhesive, junctional and cytoskeletal changes, with effects on cellular proliferation, survival and migration (Allende & Proia, 2002) . Genetic knockout of s1p1 (edg1) in mice resulted in incomplete vascular maturation caused by depletion of pericytes and vascular smooth muscle cells (Liu et al., 2000) . Furthermore, Allende et al. showed that endotheliumspecific depletion of s1p1 receptor leads to same vascular defects as a global knockout, suggesting its endothelial-specific functioning (Allende et al., 2003) . Paik et al. was first to demonstrate that S1P activation of S1P1 receptor drives microtubule polymerization via Rac signaling, which leads to trafficking of N-cadherin to polarized plasma membrane domains on endothelial cells; this in turn promotes the strengthening of cell-to-cell adhesion with pericytes (Paik et al., 2004) . Recently, it has been found that pericytes are the microvascular source of S1P that reinforces endothelial tight junctions, upon interaction with S1P1, via upregulation of VE-cadherin and N-cadherin and reducing the levels of Ang2 in the endothelial cells (McGuire et al., 2011) . In diabetes S1P secreted from pericytes promotes proliferation of endothelial cells and angiogenesis binding to S1P1-3 receptors; specifically, signaling via S1P1/3 facilitates tube formation whereas S1P2 drives the endothelial proliferation (Durham et al., 2015) .
Angiopoietin-1 and 2
Vessel stabilization and maturation are strictly dependent upon the balance of Angiopoietin-1 and Angiopoietin-2 (Ang-1/Ang-2). Ang-1 is produced by activated pericytes in a region which is far from the leading edge of nascent vessel where Ang-1 mediates the stable pericyte coverage of the otherwise leaky capillaries. Ang-1 acts paracrinally on ECs by direct interaction with Tie2 (Armulik et al., 2011; Ribatti et al., 2011) and contributes to pericyte recruitment stimulating ECs to release PDGF-B ad TGF-β (Davis et al., 1996; Suri et al., 1996; von Tell et al., 2006) . Moreover, Ang-1 stimulation directly regulates adherens junctions, reducing the phosphorylation of VE-chaderin and PECAM-1 (Gamble et al., 2000) . Ang-1 or Tie2 deficiency in mice embryos does not impede proper vascularization but impairs vessel remodeling (Suri et al., 1996; Lekas et al., 2012) . In addition, Ang-1 over-expression in transgenic mice induces hypervascularisation (Thurston et al., 1999) . Ang-1 is antagonized by Ang-2, which is produced by ECs from the leading edge and is supposed to act autocrinally through interaction with Tie2 receptor, thus mediating pericyte loss and vessel destabilization. Physiologically Ang-2 binding to Tie2 is the leading factor promoting pericyte dissociation from ECs at the beginning of vessel sprouting. However, the Ang-2/Ang-1 unbalance in favor of Ang-2 leads to an incontrollable angiogenesis, a common feature in pathological events such as diabetic retinopathy and tumor metastatisation (Durham & Herman, 2011) . In the vitreous of diabetic subjects for instance, both Ang-1 and Ang-2 levels are increased, but concentrations of Ang-2 were twice as high as that of Ang-1 (Patel et al., 2005) determining a shift towards a vessel destabilization.
Vikkula et al. were the first one to demonstrate that mutation of Tie2 leads to venous malformations and that its signaling pathway is vital for venous morphogenesis (Vikkula et al., 1996) . Further, the pro-angiogenic role of Ang-1/Tie2 signaling was shown by the genetic loss-and gain-of-function studies, where Ang-1 or Tie2-null mice embryos displayed impaired angiogenesis; moreover, microvascular basement membrane of their blood vessels was aberrantly organized and exhibited detachment of pericytes (Dumont et al., 1994; Sato et al., 1995; Suri et al., 1996) . On the other hand, Thurston et al. demonstrated that mice overexpressing Ang-1 possessed leakage-resistant blood vessels (Thurston et al., 1999) . Recombinant Ang-1 is able to resolve vascular aberrations in retina due to pericytes deficiency (Uemura et al., 2002) . A recent study has shown that Ang-1 protects endothelium from advanced glycation endproduct (AGE) injury during diabetes via strengthening endothelial cell junctions and reducing apoptosis (Zhao et al., 2015) . Together, these findings demonstrate the paracrine function of the pericyte-derived Ang-1 on endothelium. Conversely, Ang-2 ligand acts as an antagonist for the endothelial Tie2 receptor and is expressed in endothelial cells, where it promotes the pericyte loss from retinal microvessels in diabetic rats (Stratmann et al., 1998; Hammes et al., 2004) .
Transforming growth factor-β
Another important factor in stabilizing pericytes is TGF-β. This cytokine is present in latent form (LAP) in ECs and its production is regulated by an autoregulatory loop. During angiogenesis, latent TGF-β is activated upon contact with pericytes possibly involving gap junctions (Hirschi et al., 2003) . Following TGF-β activation pericytes proliferate, migrate along the nude endothelial vessel and secrete extracellular matrix. Mutations in the TGF-β receptors endoglin and ALK1, expressed both on ECs, are respectively related to the occurrence of a severe hereditary disorder namely hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disorder characterized by a multi-systemic vascular dysplasia and bleeding (McAllister et al., 1994; Johnson et al., 1996) .
The importance of the close physical association between ECs and pericytes through the gap junctions was revealed by studying two gap junction proteins: connexin-43, expressed by ECs and pericytes, and connexin-45 that is mural specific. Connexin-43 deficient mesenchymal cells do not complete mural cell differentiation when co-cultured with endothelial cells and produce latent TGF-β but are unable to produce the activated molecule. However, TGF-β treatment restores the capacity to undergo mural differentiation as well as to produce active TGF-β molecules (Theis et al., 2001; Hirschi et al., 2003) . Since mural cells stimulate endothelial basement membrane matrix formation by ECs, and because the ECM represents the natural reservoir of latent TGF-β molecules, another layer of ECs-mural cells communication using TGF-β pathway may exist through the ECM. In fact, mouse lacking αVβ8 integrin resembles phenotypes due to insufficient TGF-β activation (Cambier et al., 2005) . It was proposed that αβ family can activate TGF-β through two mechanisms: one involving the simultaneous binding of MMPs and latent TGF-β to αVβ8 and αVβ3 in order to favor the proteolytic cleavage of LAP and release of TGF-β, the second suggests that integrin αVβ3, αVβ5, and αVβ6 can release the TGF-β molecule exploiting the traction force between the cellular plasma membrane and the ECM (Annes et al., 2004; Wipff et al., 2007) .
Other paracrine regulators
Another pericytes stabilizing factor, semaphorin-3-A (Sem3A), has been recently studied for its ability to increase the pericytes coverage. Sem3A is a soluble molecule released by ECs and acts in an autocrine way on the same cells interacting with a holoreceptor composed by a Neuropilin (Nrp1) binding site and a PlexinD1 subunit responsible for a signal transduction. Grappa et al. demonstrated in mice that Sem3A works in synergy with TGF-β in inducing vessel stability although the mechanism remains unknown (Groppa et al., 2015) . A marked down-regulation of Sema3A has been observed in different types of cancer, including prostate cancer, breast cancer and glioma where it is associated with a higher incidence of metastasis and a poor prognosis (Jiang et al., 2015) .
Cytokines are other important mediators in pericytes-ECs paracrine communication. Hyldahl and co-workes demonstrated that human skeletal muscle pericytes but not satellite cells activate NF-kB following eccentric contractions and muscle damage (Hyldahl et al., 2011) . NF-kB is a transcription factor regulating the transcription of pro-angiogenic cytokines. LaBarbera and co-workers demonstrated that fostering NF-kB activation in pericytes induces an up-regulation of cytokines among which are IL-8, IP-10 and RANTES. Those factors shed from the pericytes and are able to stimulate ECs proliferation and angiogenesis in paracrine way (LaBarbera et al., 2015) .
Extracellular vesicles transfer of information between endothelial cells and pericytes
As discussed in the previous sections of this article, cell-to-cell communication is mediated by secreted bioactive molecules, such as short form peptides and proteins, but also lipids and nucleic acids can act as paracrine cell regulators. These small molecules are commonly released by cells and bind to specific receptors on target cells, which induce intracellular signaling and change the recipient cell phenotype. In addition, the signaling factors can be transferred inside the recipient cell. Recently, the concept of cell-to-cell communication is extended to include extracellular vesicles (EVs) (including microparticles (MPs) and exosomes), which were identified as a valuable transport and information tool (Yanez-Mo et al., 2015) . Extracellular RNA and in particular microRNA (miRNA) can be also found being packaged into exosomes (Valadi et al., 2007) and MPs (Zernecke et al., 2009 ), where they maintain good stability (Biomarkers et al., 2008; Chen et al., 2008; Hunter et al., 2008) and are transferred from cell-to-cell.
Exosomes
Exosomes are a subtype of membrane vesicles of approximately 30-100 nm in size that are released from the endocytic compartment of live cells (Witwer et al., 2013) . Endosomes originate from inward budding of the cytoplasmic membrane. Surface proteins of plasma membrane may be transferred to the inner membrane of the endosomes during this process. Invagination of endosomes generates exosomes through the endosomal sorting complex, required for transport (Henne et al., 2011) . Although initially considered as cell debris, exosomes have now emerged as important regulators of biological functions via transfer of protein or genetic materials. Once released, exosomes can either target neighboring cells or enter the blood stream, thus potentially reaching distant cellular targets. In co-culture experiments with pericytes and ECs, using differentially labeled cells, both cell types were able to secrete exosome as shown. In this case membrane sharing events were observed. We know that microRNAs (miRs) that control angiogenesis such as miR-15a and miR-16 are released by saphenous vein pericytes in culture embedded in exosomes (Spinetti et al., 2013) . However, the role of these secreted miRs on the endothelium needs further investigation.
Exosome release is an activated process. For instance, activation of the HIF pathway under hypoxia converts pericytes to a proangiogenic state. Under these conditions, exosome-mediated signaling is a necessary mechanism in promoting migration and tubulogenesis of ECs in vitro. Exosomes derived from activated pericytes were able to foster wound healing in a scratch assay and were also able to stimulate microvascular sprouting in spinal cord explants (Mayo & Bearden, 2015) .
Tumor cells can produce EVs that are able to modify the crosstalk between ECs and pericyte. In particular, it was demonstrated that exosomes isolated from hypoxic glioblastoma multiforme (GBM) cells are internalized by ECs and stimulate them to release paracrine cues to pericyte. Secreted growth factors and cytokines induced pericyte PI3K/AKT signaling activation and migration. This leads to a significantly enhanced induction of pericyte vessel coverage, GBM cell proliferation, as well as decreased tumor hypoxia in a mouse xenograft model (Kucharzewska et al., 2013) .
Recently, it has been demonstrated by Mirzapoiazova et al. that hyaluronan (HA), a nonsulfated glycosaminoglycan, is an important regulator of the release of EV, which is induced by formation of caveolin-enriched microdomain (CEM) (Mirzapoiazova et al., 2015) . Specifically, ECs stimulated with high molecular weight hyaluronan (HMW-HA) after~6 h initiate the release of enlargeosomes, which are enriched in neuroblast differentiation-associated protein AHNAK (also known as Desmoyokin) and Annexin II, and promote the enhancement of EC barrier; on the other hand, the low molecular weight hyaluronan (LMW-HA) induces the secretion of exosomes from ECs that results in disruption of EC barrier (Mirzapoiazova et al., 2015) .
Microparticles
MPs are cell-derived vesicles that are enclosed by a lipid bilayer, ranging from 50 nm to 1000 nm in diameter depending on their origin. Differently from exosomes that are derived from the endolysosomal pathway, MPs are generated by budding from the plasma membrane. Therefore, although they are heavily enriched in phosphatidylserine, the membrane composition of MPs reflects that of the parent cell more closely than does the membrane composition of exosomes. MPs are characterized by specific cytoplasmic proteins, certain lipid raftinteracting proteins and receptors (Boulanger & Dignat-George, 2011) .
In a recent study, Beltramo et al. demonstrated that MPs derived from mesenchymal stem cell (MSCs) play a role in vessel destabilization by interfering with the interactions between EC/pericytes and pericyte/ extracellular matrix in the diabetic retina (Beltramo et al., 2014) . MSCderived MPs are able to enter pericytes, cause pericytes detachment and migration from the substrate, and increase blood-barrier permeability. This effect is mediated at least in part by MMP-2, expressed by both secreted MPs and MP-stimulated pericytes. The same group demonstrated that under hypoxia and/or high glucose conditions MSC derived microvesicles induce the down-regulation of miR-126 in retina pericytes activating HIF-1α and VEG,F but not Ang-2 or PDGF-β pathways (Mazzeo et al., 2015) .
One of the first examples of miR-based cell-to-cell communication through microparticles comes from a study by our group, where the role of miR-503 as a mediator of pericyte-endothelial communication in limb muscle has been demonstrated. Specifically, during diabetes and limb ischemia the induction of p75 neurotrophin receptor (p75 NTR ) in ECs facilitates nuclear translocation of NF-κB p65 subunit, which binds to the promoter of miR-503 and drives its expression; at the same time, p75 NTR -initiated NF-κB activation promotes caspase-3/ ROCK-mediated release of miR-503 within the endothelial MPs, which are then taken up by the neighboring pericytes via interaction with integrins (Caporali et al., 2015) . Furthermore, endothelium-derived miR-503 down-regulates the expression of its target genes, VEGF-A and Ephrin-B2 (EFNB2), in pericytes that facilitates increased vessel permeability and reduced post-ischemic angiogenesis in the limb muscles via impaired proliferation and migration of pericytes (Caporali et al., 2015) . Moreover, silencing of VEGF-A in pericytes attenuates its role in promoting ECs survival, migration and angiogenesis (Darland et al., 2003; Franco et al., 2011) , while EFNB2 downregulation leads to a diminished association of pericytes within the vessels (Foo et al., 2006) . Another group reported a passage of EVs from cultured human brain ECs to pericytes induced by inflammation. Stimulation with inflammatory cytokines and endotoxin immediately induced the shedding of EVs which were selectively loaded with a set of miRs like miR-328-3p and let-7d-3p regulating VEGF-B which may mediate pathological neovascularization and/or vascular leakage in response to inflammation of endothelial cells (Yamamoto et al., 2015) .
The two faces of the same coin: pericytes in regeneration and diseases
Pericytes are not only vessels stabilizers but they are able to transdifferentiate at least in vitro in other cell types like adipocytes, chondrocytes, osteocytes, myocytes, and neural cells (Birbrair et al., 2012a (Birbrair et al., , 2012b contributing to regenerative mechanisms following tissue injury. The ability of pericytes to differentiate into different lineages is a consequence of their mesenchymal origin but compared to MSCs pericytes are a more homogeneous population with a higher differentiation potential (Corselli et al., 2013) . Studies on mice models of bone critical size fracture demonstrated that pericyte sorted from adipose tissue are more efficient in driving bone regeneration compared with MSCs from the same tissue. Specifically, NG2 + /CD146 + /CD45 − pericytes seeded onto bone scaffold implanted into the broken mouse bone were able to differentiate into osteoblasts and colonize more efficiently the holes of the scaffold contributing to the complete regeneration of the tissue (Konig et al., 2016) . However, the regenerative properties of pericytes depend on their tissue origin. For instance, pericytes are crucial in the process of wound healing, although pericytes from skin or kidney can contribute to fibrosis of the wounded tissue since they can trans-differentiate into collagen secreting myofibroblasts (Lin et al., 2008; Goritz et al., 2011; Chang et al., 2012; Birbrair et al., 2014) . In addition, pericytes are also involved in the pathogenesis of diverse diseases. Indeed, pericytes have recently discovered to be involved in neurodegenerative disorders. Deposition of Aβ oligomers in blood-brain barrier pericytes contributes to a loss of pericytes by apoptosis. This event also leads to regression of brain capillaries. The subsequent toxin accumulation may then result in injury, dysfunction and ultimately neuronal cell death in the vicinity of regressed vessels (Bell et al., 2010) . Another typical pericyte disorder is diabetic retinopathy, a consequence of type 1 and 2 diabetes characterized by a breakdown of the blood retinal barrier (BRB). The BRB is a complex system of nonfenestrated capillaries pericytes and glial cells processes preventing passage of large molecules into the retinal pigment epithelial cells. The breakdown of the BRB is mainly due to loss of pericytes, induced by an increase in Ang-2 accompanied by a VEGF-A dependent disruption of junction complexes between adjacent ECs. This in turn increases the paracellular permeability and also induces vessel degradation. This initial vessel degradation is accompanied by an aberrant compensatory angiogenesis. Healthy pericytes have been proposed for cell therapy approaches. Pericytes from mouse adipose tissues (mASCs) were tested in a mouse model of diabetic retinopathy (Akimba mice) in an attempt to demonstrate a possible use in the field of cell therapy. The injection of mASCs in the eye of Akimba mice revealed the ability of these cells to integrate in the abluminal side of the endothelium, which is the natural pericyte location, and furthermore they were able to reduce the magnitude of retinal vessels damage especially upon pre-conditioning with TGF-β. Moreover, the injection of the cellular suspension did not induce teratoma formation, thus reducing the concerns about safety (Mendel et al., 2013) .
Our group recently demonstrated that pericytes residing in the muscle of patients with diabetes and critical limb ischemia are impaired in their proliferation and differentiation towards myotube ability. Importantly diabetic pericytes were anti-angiogenic in vitro when co-cultured with endothelial cells. All these features were attributed to a deregulation of the oxidative stress regulatory mechanisms and where reverted by antioxidant treatments pointing at potential new therapeutic approaches to improve vascularization via targeting pericytes (Vono et al. in press) .
New investigations point at cancer angiogenesis as a "pericyte disorder". Aberrant tumor vessels indeed are responsible for rapid tumor growth, metastasis and reduced efficacy of therapies especially in solid tumors where aberrant vessels are not able to adequately perfuse the tissue. Pericytes have a pivotal role in these processes, and the pericyte coverage in localized tumors is not homogeneous. Some vessels especially those surrounding the tumor, are highly covered and this creates a sort of barrier impeding the access to the cells of the immune system and to therapeutic agents (Bergers & Hanahan, 2008) . In contrast, highly metastatic tumors show a reduced pericyte coverage, which causes leakiness of the endothelial wall and cancerous cells extravasations and dissemination (Meng et al., 2015) . In this case multi-target intervention acting on both angiogenesis and pericyte coverage modulation would be more beneficial.
Pericyte signaling as pharmacological target: implications on pericyte coverage and vessel maturation
Pericytes are crucial for blood vessel formation and function and are therefore prospective targets for both anti-angiogenic and proangiogenic therapies. A classical vessel maturation target is the PDGF-Β axis. PDGF-B is released from the sprouting endothelial cells, which chemoattracts pericytes that express PDGFR-β. Many small multitargeting kinase inhibitors of PDGF-B signaling have been investigated for their effects on pericytes and angiogenesis. Selective inhibitors of PDGFR-β that are of interest and currently being tested in clinical trials include CP-673451 (Roberts et al., 2005) and orantinib (Laird et al., 2000) . However, a recent study demonstrated severe cardiotoxicity of CP-673451 due to pericyte depletion and coronary microvascular dysfunction (Chintalgattu et al., 2013) .
Among PDGFR inhibitors, imatinib (Glivec; Novartis), which mainly targets PDGFRs and cKIT, has been shown to inhibit lymphoma angiogenesis by targeting pericytes. Tumor growth inhibition, on this particular case, was associated with decreased microvascular density and increased vascular leakage (Ruan et al., 2013) . Simultaneous targeting of VEGFRs, PDGFRs and fibroblast growth factor receptors (FGFRs) by nintedanib (Ofev; Boehringer Ingelheim) resulted in a considerably increased overall survival for patients with non-smallcell lung cancer (Reck et al., 2014) . Axitinib, an inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR-β, and c-kit, reduced microvessel density and EC sprouting, increasing pericytes and ECs coverage in a spontaneous pancreatic insulinoma model (Nakahara et al., 2006) . Often these chemical compounds can also target other receptor tyrosine kinases to various degrees. Moreover, depending on the organ and disease, the various PDGFR-β inhibitors will have different effects on mural cells and other PDGFR-expressing cells, such as fibroblasts.
Interestingly, PDGFD overexpression can normalize tumor vessels and increase drug delivery by affecting the blood vessel morphology and increasing perivascular cell coverage. This vessel maturation can attenuate vascular hyperpermeability and improve tissue penetration of chemotherapeutic agents (Liu et al., 2011) .
Pharmacological blockade of VEGF-A signaling reverts-although transiently-the aberrant features of tumor vasculature, leading to essel normalization due to an increase of pericyte coverage (Jain, 2005) . Bevacizumab, a humanized monoclonal antibody anti-VEGF-A, stabilized the vessels in mice bearing human neuroblastoma xenografts, further showing reductions in microvessel density and vessel length, diameter, and tortuosity. Importantly, tumor vessels also appeared significantly more mature and covered by pericytes (Dickson et al., 2007) . The effects of aflibercept (anti-VEGF drug), a recombinant fusion protein consisting of VEGF-binding portions from the extracellular domains of human VEGFR1 and 2, on the structure of tumor vessels have been examined in the spontaneous murine model of pancreatic beta-cell derived tumors (Inai et al., 2004) . Such inhibition of VEGF signaling led to a reduction in neovascular sprouts and decrease in the endothelial fenestration and tightened associations between ECs and pericytes.
Another example of a molecular pathway that regulates vessel normalization is the ANG-TIE2 receptor axis, which controls vessel maturation. Neutralization of Ang-2 with Li-7, a peptide specifically neutralizing Ang-2, resulted in normalized vessels (Falcon et al., 2009 ). In particular, vessels were narrower with a more uniform morphology and less tortuosity. In addition, increased pericyte coverage was observed, and there was a tightening of association between pericytes and ECs.
When restoration of pericytes function is needed to improve therapeutic angiogenesis, like in the case of peripheral limb ischemia, different strategies may be needed. Data from our group (Vono et al. in press) point at potential beneficial effect of antioxidant treatments for the biological function of muscle pericytes that deserve further investigation.
Finally, communication between ECs and pericytes occurs also through microvesicles, including MPs and exosomes, which shuttle proteins, lipids, microRNAs and mRNAs between cells. In the United States, a clinical trial is investigating exosomes as an alternative vehicle to liposomes for drug delivery (ClinicalTrials.gov identifier: NCT01294072). As drug delivery vehicles, exosomes could, in principle, be injected into the target tissue and deliver their cargo into the vascular beds. An exciting possibility is that exosomes could be designed to express surface molecules that specifically target pericytes.
Conclusions
Targeting pericyte to efficiently tune their stabilizing effect on the endothelium is a challenging but intriguing promise for treatment of diseases with impaired angiogenesis. The initial therapeutic idea of restoring normal vasculature that acts only on the regulation of ECs in angiogenesis, thereby stimulating or counteracting VEGF signaling, is overcome in favor of a combinatory therapeutic approach that targets also PDGF-B, TGF-β and Ang-2 pathways. However, studies are restricted to certain pathologies such as tumors and most of them are preclinical, so concern about how to monitor pericyte coverage in patients limits the investigation. To this end, novel imaging approaches will improve our understanding of pericytes dynamics, functionality, and phenotypic flexibility. The ability to monitor and track endogenously labeled pericytes in vivo using high-resolution intravital imaging approaches enables us to observe the dynamic behaviors of cells in different tissues. A full appreciation of how pericytes move and interact with ECs during vessel formation and in diseases will not only tell us more about how these processes are regulated, but should also unveil many new potential methods to influence the microenvironment in order to steer cellular functions towards the restoration of homeostasis. New indications will also probably be found for existing drugs as a result of a more detailed molecular understanding of the communication between pericytes and ECs.
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